Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..
Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults
Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del..
Evidence-based recommendations on nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating advanced melanoma (skin cancer)
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel
Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene..
Evidence-based recommendations on ceritinib (Zykadia) for advanced anaplastic lymphoma kinase positive non-small-cell lung cancer...
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia
Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)
Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma with a BRAF V600 mutation
Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) for treating type 2 diabetes in adults
Evidence-based recommendations on ImmunoCAP ISAC 112 and Microtest for multiplex allergen testing to diagnose allergy and predict the risk of allergic reaction
Evidence-based recommendations on PlGF-based testing to help diagnose suspected pre-eclampsia
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx), paclitaxel, trabectedin (Yondelis) and gemcitabine...
Evidence-based recommendations on ruxolitinib (Jakavi) for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.
Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.
Evidence-based recommendations on therapeutic monitoring of TNF-alpha inhibitors in Crohn’s disease
Evidence-based recommendations on the MiniMed Paradigm Veo and Vibe and G4 PLATINUM CGM sensor-augmented pump therapy systems for type 1 diabetes
Evidence-based recommendations on the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for identifying bloodstream bacteria and fungi
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer before chemotherapy is indicated
This guidance has been updated and replaced by NICE technology appraisal guidance 412.
NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…
Evidence-based recommendations on olaparib (Lynparza)
Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.
Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.
Evidence-based recommendations on ramucirumab (Cyramza)
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…
Evidence-based recommendations on imatinib (Glivec) for treating chronic myeloid leukaemia (CML)
This guidance has been updated and replaced by NICE technology appraisal guidance 458.
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa (MPS IVA)
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating locally advanced or metastatic non-small-cell lung cancer
This guidance has been updated and replaced by NICE technology appraisal guidance 433.
Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)
Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults
Evidence-based recommendations on ciclosporin (Ikervis) for treating dry eye disease that has not improved despite treatment with artificial tears
This guidance has been withdrawn because Bristol-Myers Squibb has discontinued daclatasvir (Daklinza).
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults
Evidence-based recommendations on VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions